Peripheral arterial disease: A guide for nephrologists

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 4, 2007, Pages 839-846

  DeLoach, Stephanie S ^a   Mohler III, Emile R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; KIDNEY DISEASE; NEPHROLOGY; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; REVIEW; RISK FACTOR;

HUMANS; KIDNEY DISEASES; NEPHROLOGY; PERIPHERAL VASCULAR DISEASES; PRACTICE GUIDELINES; RISK FACTORS;

EID: 34548828010     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04101206     Document Type: Review

References (76)

1. Go AS, Chertow GM, Fan D, McCulloch CE: Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. N Engl J Med 351: 1296-1305, 2004
2. Shilpak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, Mcclellan MB: Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 137: 555-562, 2002
3. Townsend RR: Cardiac mortality in chronic kidney disease: A clearer perspective. Ann Intern Med 137: 615-616, 2002
4. O'Hare AM: Management of peripheral arterial disease in chronic kidney disease. Cardiol Clin 23: 225-236, 2005
5. O'Hare AM: High prevalence of peripheral arterial disease in persons with renal insufficiency: Results from the National Health and Nutrition Examination Survey. Circulation 109: 320-323, 2004
6. Leskinen Y, Salenius JP, Lehtimaki T, Huhtala H, Saha H: The prevalence of peripheral arterial disease and medial artery calcification in patients with chronic renal failure: Requirements for diagnostics. Am J Kidney Dis 40: 472-479, 2002
7. O'Hare AM, Vittinghoff E, Hsia J, Shilpak MG: Renal insufficiency and the risk of lower extremity peripheral arterial disease: Results from the Heart and Estrogen/Progestin Replacement Study. J Am Soc Nephrol 15: 1046-1051, 2004
8. Wattanakit K, Folsom AR, Selvin E, Coresh J, Hirsch AT, Weatherley BD: Kidney function and risk of peripheral arterial disease: Results from the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol 18: 629-636, 2007
9. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, Bell K, Caporusso J, Durand-Zaleski I, Komori K, Lammer J, Liapis C, Novo S, Razavi M, Robbs J, Schaper N, Shigematsu H, Sapoval M, White C, White J; TASC II Working Group: Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 33: S1-S75, 2007
10. Eggers PW, Gohdes D, Pugh J: Nontraumatic lower extremity amputations in the Medicare end-stage renal disease population. Kidney Int 56: 1524-1533, 1999
11. Jaar BG, Astor BC, Berns JS, Powe NR: Predictors of amputation and survival following lower extremity revascularization in hemodialysis patients. Kidney Int 65: 613-620, 2004
12. Ramdev P, Rayan SS, Sheahan M, Hamdan AD, Logerfo FW, Akbari CM, Campbell DR, Pomposelli FB Jr: A decade of experience with infrainguinal revascularization in dialysis-dependant population. J Vasc Surg 36: 969-974, 2002
13. Centers for Disease Control and Prevention (CDC): Lower extremity disease among persons aged ≥40 years with and without diabetes - United States, 1999-2002. MMWR Morb Mortal Wkly Rep 54: 1158-1160, 2005
14. Selvin E, Erlinger TP: Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 110: 738-743, 2004
15. USRDS: United States Renal Data System Annual Data Report, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Division of Kidney Urologic and Hematologic Diseases, 2000, pp 339-348
16. Meijer WT, Grobbee DE, Hunink MGM, Hofman A, Hoes AW: Determinants of peripheral arterial disease in the elderly: The Rotterdam Study. Arch Intern Med 160: 2934-2938, 2000
17. Hirsch AT, Criqui MH, Treat-Jacobson D: Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286: 1317-1324, 2001
18. Cheung AK, Sarnak MJ, Yah G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58: 353-362, 2000
19. United States Renal Data System: Excerpts from the USRDS 2003 annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 42: S1-S226, 2004
20. Boaz M, Weinstein T, Matas Z, Green MS, Smetana S: Peripheral vascular disease and serum phosphorus in hemodialysis: A nested case-control study. Clin Nephrol 63: 98-105, 2005
21. Cooper BA, Penne EL, Bartlett LH, Pollack CA: Protein malnutrition and hypoalbuminemia as predictors of vascular events and mortality in ESRD. Am J Kidney Dis 43: 61-66, 2004
22. O'Hare AM, Hsu CY, Bacchetti P: Peripheral vascular disease risk factors among patients undergoing hemodialysis. J Am Soc Nephrol 13: 497-503, 2002
23. Manns BJ, Burgess ED, Hyndman ME, Parsons HG, Schaefer JP, Scott-Douglas NW: Hyperhomocysteinemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am J Kidney Dis 34: 669-677, 1999
24. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hermekens CH: Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 87: 425-428, 1998
25. Hirsch AT: ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines. Circulation 113: e463, 2005
26. Mohler ER: Peripheral arterial disease: Identification and implications. Arch Intern Med 163: 2306-2314, 2003
27. Dunbar RL, Mohler ER 3rd: The unsung perils of a peripheral arterial disease: A malady in search of a patient. Prev Cardiol 8: 108-113, 2005
28. Lane JS, Vittinghoff E, Lane KT, Hiramoto JS, Messina LM: Risk factors for premature peripheral vascular disease: Results for the National Health and Nutrition Examination Survey, 1999-2002. J Vasc Surg 44: 319-325, 2006
29. Fishbane S, Youn S, Flaster E, Adams G, Maesaka JK: Ankle-arm blood pressure index as a predictor of mortality in hemodialysis patients. Am J Kidney Dis 27: 668-672, 1996
30. Ono K, Tsuchida A, Kawai H, Matsuo H, Wakamatsu R, Maeawa A, Yano S, Kawada T, Nojima Y: Ankle-brachial blood pressure index predicts all-cause and cardiovascular mortality in hemodialysis patients. J Am Soc Nephrol 14: 1591-1598, 2003
31. Stack AG: Coronary artery disease and peripheral vascular disease in chronic kidney disease: An epidemiologic perspective. Cardiol Clin 23: 285-298, 2005
32. Mcdermott MM, Greenland P, Liu K, Gurainik JM, Criqui MH, Dolan NC, Chan C, Celic L, Pearce WH, Schneider JR, Sharma L, Clark E, Gibson D, Martin GJ: Leg symptoms in peripheral arterial disease: Associated clinical characteristics and functional impairment. JAMA 286: 1599-1606, 2001
33. McGee SR, Boyko EJ: Physical examination and chronic lower-extremity ischemia: A critical review. Arch Intern Med 158: 1357-1364, 1998
34. Resnick HE: Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality. Circulation 109: 733-739, 2004
35. Makisalo H, Lepantalo M, Halme L, Lund T, Peltonen S, Salmela K, Ahonen J: Peripheral arterial disease as a predictor of outcome after renal transplantation. Transplant Int 11[Suppl 1]: S140-S143, 1998
36. Jacoby JS, Mohler ER, Rader DJ: Noninvasive atherosclerosis imaging for predicting cardiovascular events and assessing therapeutic interventions. Curr Atheroscler Rep 6: 20-26, 2004
37. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS: Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17: 2359-2362, 2006
38. Grobner T: Gadolinium: A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis. Nephrol Dial Transplant 21: 1104-1108, 2006
39. Jonason T, Bergstrom R: Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand 221: 253-260, 1987
40. Foley RN, Herzog CA, Collins AJ: Smoking and cardiovascular outcomes in dialysis patients: The United States Renal Data System Wave 2 Study. Kidney Int 63: 1462-1467, 2003
41. deGroot E, Jukema JW, Montauban AD: B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: A report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol 31: 1561-1567, 1998
42. Mohler ER 3rd, Hiatt WR, Creager MA: Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108: 1481-1486, 2003
43. Mcdermott MM, Guralnik JM, Greenland P: Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 107: 757-761, 2003
44. Mondillo S, Ballo P, Barbati R: Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic. Am J Med 114: 359-364, 2003
45. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360: 7-22, 2002
46. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G; Cholesterol and Recurrent Events (CARE) Trial Investigators: Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 138: 98-104, 2003
47. Wanner C, Krane V, Marz W, Olschewski M, Mann JFE, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005
48. Baigent C, Landry M: Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 84: S207-S210, 2003
49. Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, Yusuf S; HOPE Study Investigators: Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 25: 17-24, 2004
50. Wolosker N, Nakano L, Rosoky R, Puech-Leao P: Evaluation of walking capacity over time in 500 patients with intermittent claudication who underwent clinical treatment. Arch Intern Med 163: 2296-2300, 2003
51. Zwierska I, Walker RD, Choksy SA, Male JS, Pockley AG, Saxton JM: Upper- vs lower-limb aerobic exercise rehabilitation in patients with symptomatic peripheral arterial disease: A randomized controlled trial. J Vasc Surg 42: 1122-1130, 2005
52. Brendle DC, Joseph LJ, Corretti MC: Effects of exercise rehabilitation on endothelial reactivity in older patients with peripheral arterial disease. Am J Cardiol 87: 324-329, 2001
53. Gustafsson T, Kraus WE: Exercise-induced angiogenesis-related growth and transcription factors in skeletal muscle, and their modification in muscle pathology. Front Biosci 6: D75-D89, 2001
54. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT: Exercise training for claudication. N Engl J Med 347: 1941-1951, 2002
55. Mcdermott MM, Liu K, Criqui MH, Greeland P, Gurainik JM, Tian L, Schneider JR, Pearce WH, Tan J, Martin GJ: Physical performance in peripheral artery disease: A slower rate in decline in patients who walk more. Ann Intern Med 144: 10-20, 2006
56. Clagett GP, Sobel M, Jackson MR: Antithrombotic therapy in peripheral arterial occlusive disease. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 609S-626S, 2004
57. CAPRIE Steering Committee: A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 348: 1329-1339, 1996
58. Norgren L, Hiatt WR, Dormandy JA, Nehler KAH, Fowkes FGR: Inter-Society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 45[suppl 1]: S5-S67, 2007
59. Hongo RH, Ley J, Dick SE, Yee RR: The effect of dopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 40: 231-237, 2002
60. Regensteiner JG, Ware JE, McCarthy WJ, Zhang P, Forbes WP, Heckman J, Hiatt WR: Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: Meta-analysis of six randomized controlled trials. J Am Geriatr Soc 50: 1939-1946, 2002
61. Beebe HG, Dawson DL, Cutler BS: A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial. Arch Intern Med 2041-2050, 1999
62. Mohler ER, Beebe HG, Salles-Cuhna S: Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication. Vasc Med 6: 151-156, 2001
63. Reilly MP, Mohler ER: Cilostazol: Treatment of intermittent claudication. Ann Pharmacother 35: 48-56, 2001
64. Dormandy JA, Rutherford RB: Management of peripheral arterial disease (PAD). J Vasc Surg 31: S1-S296, 2000
65. O'Hare AM, Sidawy AN, Feinglass J, Merine KM, Daley J, Khuri S, Henderson WG, Johansen K: Influence of renal insufficiency on limb loss and mortality after initial lower extremity surgical revascularization. J Vasc Surg 39: 709-716, 2004
66. O'Hare AM, Feinglass J, Sidawy AN, Bacchetti P, Rodriguez RA, Daley J, Khuri S, Henderson WG, Johansen K: Impact of renal insufficiency on short-term morbidity and mortality after lower extremity revascularization: Data from the Department of Veterans Affairs' National Surgical Quality Improvement Program. J Am Soc Nephrol 14: 1287-1295, 2003
67. Zannetti S, L'Italien GJ, Cambria RP: Functional outcome after surgical treatment for intermittent claudication. J Vasc Surg 24: 65, 1996
68. DeBakey ME, Glaeser DH: Patterns of atherosclerosis: Effect of risk factors on recurrence and survival: Analysis of 11,890 cases with more than 25-year follow-up. Am J Cardiol 85: 1045-1053, 2000
69. Dorffler-Melly J: Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev CD0000535, 2003
70. Collins TC, Souchek J, Beyth RJ: Benefits of antithrombotic therapy after infrainguinal bypass grafting: A meta-analysis. Am J Med 117: 93-99, 2004
71. Reddan DN, Marcus RJ, Owen WF, Szczech LA, Landwehr DM: Long-term outcomes of revascularization for peripheral vascular disease in end-stage renal disease patients. Am J Kidney Dis 38: 57-63, 2001
72. Korn P, Hoenig SJ, Skillman JJ, Kent KC: Is lower extremity revascularization worthwhile in patients with end-stage renal disease? Surgery 128: 472-479, 2000
73. Speckman RA, Frankenfield DA, Roman SH, Eggers PW, Bedinger MR, Rocco MV, McClellan WM: Diabetes is strongest risk factor for lower extremity amputation in new hemodialysis patients. Diabetes Care 27: 2198-2203, 2004
74. Taylor SM, Kallbaugh CA, Blackhurst DW, Hamontree SE, Cull DL, Messich HS, Robertson RT, Langan EM 3rd, York JW, Carsten CG 3rd, Snyder BA, Jackson MR, Youkey JR: Preoperative clinical factors predict postoperative functional outcomes after major lower limb amputation: An analysis of 553 consecutive patients. J Vasc Surg 42: 227-235, 2005
75. Aulivola B, Hile CN, Hamdan AD, Sheahan MG, Veraldi JR, Skillman JJ, Campbell DR, Scovell SD, LoGerfo FW, Pomposelli FB Jr: Major lower extremity amputation: Outcome of a modern series. Arch Surg 139: 395-399, 2004
76. Rith-Najarian S, Gohdes D: Preventing amputations among patients with diabetes on dialysis. Diabetes Care 23: 1445-1446, 2000